Fundraising Fox
Pulmocide
Founded 2013 · 18 employees on LinkedIn · 18 known investors
Find your way into Pulmocide
Sign up to see every warm intro you have to Pulmocide
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Pulmocide team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.
Founders & leadership
Pulmocide was founded in 2013 by Pete Strong, Garth Rapeport, Kazuhiro Ito, and John Murray.
Investors · 18
How we know: Adjuvant Capital's portfolio page · a partner's Signal profile · globenewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Asahi Kasei Corporate Venture Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Dementia Discovery Fund's portfolio page · Not right? Tell us
How we know: F-Prime Capital's portfolio page · globenewswire.com · Not right? Tell us
How we know: Longwood Fund's portfolio page · globenewswire.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: SR One Capital Management's portfolio page · Not right? Tell us
How we know: SV Health Investors's portfolio page · globenewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Vivo Capital's portfolio page · pulmocide.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: globenewswire.com · Not right? Tell us
How we know: funding news · uktech.news · Not right? Tell us
Also in the syndicate · 7
Funding
SEC filings, press & company announcements$82M disclosed across 2 of 4 rounds · 2017–2022
- $52MSeries C extension roundDec 2022 · 2 sources
Pictet Alternative Advisors (lead), Vivo Capital (lead), Adjuvant Capital, Asahi Kasei Pharma, Cystic Fibrosis Foundation, F-Prime Capital, IP Group plc, Jeito Capital, Johnson & Johnson Innovation – JJDC, Inc., Longwood Fund, SR One, SV Health Investors
Source ↗ - Undisclosed amountSeries CMay 2021
Jeito Capital (lead), Adjuvant Capital, Asahi Kasei Pharma, F-Prime Capital, IP Group plc, Johnson & Johnson Innovation – JJDC, Inc., Longwood Fund, SR One, SV Health Investors
Source ↗ - $30MSeries BMar 2017 · 2 sources
F-prime, Johnson & Johnson, SV Life Sciences, Touchstone Innovations
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Pulmocide do?
- Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis. Its lead investigational drug, opelconazole, is an inhaled antifungal agent in Phase 3 trials for patients with invasive pulmonary aspergillosis not responding to standard care.
- Who founded Pulmocide?
- Pulmocide was founded by Pete Strong, Garth Rapeport, Kazuhiro Ito, John Murray in 2013.
- Who are Pulmocide's investors?
- Pulmocide's investors include Adjuvant Capital, Asahi Kasei Corporate Venture Capital, Dementia Discovery Fund, F-Prime Capital, Jeito Capital, Longwood Fund, SR One Capital Management, SV Health Investors and 3 more.
- How much funding has Pulmocide raised?
- Pulmocide has disclosed $82M raised across 2 of its 4 known rounds.